Hepatitis E virus infection increases the risk of diabetes and severity of liver disease in patients with chronic hepatitis C virus infection

Patricia Momoyo Yoshimura Zitelli1,2, Michele Gomes-Gouveia1,3, Daniel F. Mazo1,4, IV Julio da Motta Singer5, III Claudia P.M.S. Oliveira6,7, Alberto Queiroz Farias1,8, João Renato Pinho1,9, Ryan Yukimatsu Tanigawa10,11, Venâncio Avancini Ferreira Alves12,13, Flair José Carrilho14,15, Mário Guimarães Pessoa16,17, *Corresponding author. E-mail: mgpessoa@usp.br

1Divisão de Gastroenterologia e Hepatologia Clínica, Departamento de Gastroenterologia, Hospital das Clínicas HC FMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, BR. 2 Departamento de Patologia, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, BR. 3 Departamento de Estatística, Instituto de Matemática e Estatística, Universidade de São Paulo, São Paulo, SP, BR. 4 Divisão de Gastroenterologia (Gastrocentro), Faculdade de Ciências Médicas, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, BR.

Zitelli PMY, Gomes-Gouveia M, Mazo DF, Singer JM, Oliveira CPMS, Farias AQ, et al. Hepatitis E virus infection increases the risk of diabetes and severity of liver disease in patients with chronic hepatitis C virus infection. Clinics (Sao Paulo). 2021;76:e3270

OBJECTIVES: Co-infection with hepatitis A or B viruses may aggravate liver injury in patients infected with hepatitis C virus (HCV). However, few studies have assessed co-infection with hepatitis E virus (HEV) and HCV. Therefore, this study aimed to assess the prevalence and impact of HEV infection among Brazilian patients with chronic HCV infection.

METHODS: This observational study included adult patients with chronic HCV infection who were naive to antiviral therapy from January 2013 to March 2016. A total of 181 patients were enrolled, and HEV serology and PCR were performed for all patients.

RESULTS: Seropositivity for anti-HEV IgG was detected in 22 (12.0%) patients and anti-HEV immunoglobulin M in 3 (1.6%). HEV RNA showed inconclusive results in nine (4.9%) patients and was undetectable in the remaining patients. HEV serology positive patients had more severe liver disease, characterized by liver fibrosis ≥ 3 versus ≤ 2 (p < 0.001), Aspartate Aminotransferase-to-Platelet Ratio Index of ≥ 1.45 (p = 0.003), and Fibrosis-4 score of ≥ 3.25 (p = 0.001). Additionally, the odds of HEV-positive patients developing diabetes mellitus were 3.65 (95% CI 1.40-9.52) times the corresponding odds of HEV-negative patients. A case-control-based histological analysis (n=11 HEV-HCV-positive patients and n=22 HCV-positive patients) showed no significant differences between the groups.

CONCLUSIONS: This prevalence is higher than that reported in previous studies of the general population in Brazil. Thus, HEV infection may influence the severity of liver disease and may represent an additional risk of developing diabetes mellitus in patients with HCV infection.

KEYWORDS: Hepatitis E; Hepatitis C, Chronic; Diabetes Mellitus; Liver Cirrhosis.

INTRODUCTION

Hepatitis E virus (HEV) is characterized by a single-stranded RNA virus of variable prevalence, which belongs to the Hepeviridae family. Four major HEV genotypes have been reported. Genotypes 1 and 2 cause acute and epidemic diseases in humans and are more frequent in developing countries, where poor sanitary conditions prevail, either by fecal–oral transmission or from contaminated water or food. Genotypes 3 and 4 are typically transmitted via zoonosis, raw or undercooked pork consumption, or wild animal meat consumption (1-5).

The clinical course is benign with mild and self-limited symptoms in most cases, as reported by the initial series of cases among travelers to endemic regions of Asia, Africa, and the Middle East. Chronification is more likely to occur in immunocompromised hosts (6).

Previous studies have shown that patients with chronic hepatitis C virus (HCV) infection may have liver injury aggravated by co-infection with hepatitis A virus or hepatitis B virus (HBV) (7). However, few studies have evaluated the impact of HEV infection in HCV-infected patients. A study from Turkey demonstrated that among 190 HBV-infected patients (13.7%), 174 HCV-infected patients (54%), and 178 healthy individuals (15.7%) had anti-HEV IgG antibody positivity for HEV. Therefore, the screening and development of
educational programs aimed at the prevention of this infection in Brazilians is justified (8). Data on the HEV role in HCV-infected patients in Brazil are scarce, whereas HEV is relatively uncommon, with prevalence of 1%–12.9%. In 1995, Pang et al. first reported data regarding HEV infection in Brazil and identified HEV seroprevalence in 6% of gold mine workers in Amazonas (9). Recent studies have shown similar blood donor results, with prevalence of 4.3% and 9.8% in Rio de Janeiro and São Paulo, respectively (10,11). More recent data have shown prevalence of 6% in the adult population, 7% in blood donors, and 3% in the general population (12).

HEV has become a public health issue, with a significant increase in morbidity and mortality worldwide. A meta-analysis study in developed countries performed on blood donors showed the seroprevalence of anti-HEV IgG antibodies using the Wantai HEV IgG ELISA kit, with 52.5%, 39.1%, 34%, and 22.4% in different regions of France, 49.6% in Poland, 49% in Italy, and 31% in the Netherlands (10). Three categories of risk were demonstrated: high risk (France, the Netherlands, and Poland), medium risk (Austria, Denmark, Norway, Spain, the United Kingdom, and the United States), and low risk (Canada, Scotland, Ireland, Australia, and New Zealand) (10). The main characteristics associated with high seroprevalence were advanced age; male sex; contact with animals (pig farm workers or persons with occupational exposure to pigs); raw or undercooked pork consumption; and frequent consumption of beef, smoked meats, and oysters. Low prevalence is associated with bottled water consumption (10).

Thus, we conducted this study to assess the prevalence and impact of positive markers of HEV on the severity of liver fibrosis and morbidity among Brazilian patients with chronic HCV infection.

METHODS

Patients and study design

This was an observational cross-sectional study of adult patients with chronic HCV infection who were naïve to antiviral treatment and followed up at the outpatient liver clinic of the Department of Gastroenterology of the University of São Paulo School of Medicine. This service provides tertiary health care for a broad population of 18 million people. Patients were prospectively and consecutively recruited from January 2013 to March 2016.

We included those patients whose recent data suggested that interferon and ribavirin (standard HCV treatment at that moment) could also treat HEV infection, with HCV RNA positivity for at least 6 months, and with no previous antiviral HCV treatment (5). In contrast, we excluded those with HBV or human immunodeficiency virus co-infection, other chronic liver diseases including alcoholic liver injury and non-alcoholic fatty liver disease, use of immunosuppressive therapy, or refusal to participate in the study.

We evaluated a total of 727 HCV-seropositive patients for enrollment. Among them, we excluded 106 patients discharged from the clinic, 406 who received antiviral therapy, and one with HBV co-infection. Then, we also excluded the 214 patients naïve for HCV treatment and 33 who underwent kidney transplantation because they were under immunosuppressive therapy. Finally, a total of 181 patients were included for analysis (Figure 1).

Baseline demographic, clinical, and laboratory data were obtained from all participants. They included complications of liver disease (ascites, esophageal varices, and hepatic encephalopathy) and associated diseases.

Liver fibrosis assessment

Of the 181 patients included in the study, 96 underwent liver biopsy according to routine clinical care for HCV-infected patients. We performed a case–control-based histological analysis encompassing the 11 cases of HEV-positive markers in patients who underwent a liver biopsy to analyze whether any histological characteristics were specific to HEV infection. In addition, they were matched for age, sex, HCV genotype, and severity of liver fibrosis on liver biopsy with 22 HEV-negative markers in HCV-positive patients.
Liver biopsy slides were analyzed to compare the histological aspects of HCV infection in individuals with HCV infection and positive serological markers for HEV. These cases were reviewed by an experienced liver pathologist, who was blinded to the HEV serological status and reclassified according to the METAVIR score as follows: F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis and few septa extending into lobules; F3, numerous septa extending to adjacent portal tracts or terminal hepatic venules; and F4, cirrhosis. In addition, the following histological parameters were registered: portal inflammatory infiltrate, interface and parenchymal activity, steatosis, ballooning, Mallory hyaline, portal alterations, cholestatic changes, and lobular inflammatory cells.

For liver fibrosis evaluation, non-invasive methods were applied at the time of HEV serology assessment. Liver stiffness was determined using FibroScan® 402 (EchoSens, Les Ulis, France) equipped with a standard M probe. Advanced liver fibrosis (≥ F3) was defined as a liver stiffness measurement of >9.5 kPa. The Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) score was also computed using this formula: ([aspartate aminotransferase level/upper limit of normal] × 100)/platelet count × 10^9/L. APRI values of ≥ 1.45 were interpreted as advanced hepatic fibrosis. Fibrosis-4 index (FIB-4) score was computed using the formula [age] × aspartate aminotransferase level × (platelet count × 10^9/L) × (alanine transaminase level^0.5). FIB-4 values of ≥ 3.25 were interpreted as advanced hepatic fibrosis.

**HEV assessment**
HEV antibodies [immunoglobulin (Ig) M and IgG] were investigated in serum samples using commercial ELISA kits (RecomWell HEV, Mikrogen GmbH, Neuried, Germany). Immunoblotting was performed using RecomLine Kits (Mikrogen GmbH) to confirm indeterminate ELISA results. The occurrence of ongoing HEV infection was investigated in all patients using quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR). HEV RNA was extracted from plasma using the QIAmp® Viral RNA Spin Kit (QIAGEN, Hilden, Germany). HEV RNA was eluted in 60 μL buffer, and 5 μL was used for amplification by one-step real-time PCR using the Quantifast Pathogen RT-PCR + IC kit (QIAGEN), primers and a TaqMan probe, which targets the highly conserved ORF3 region (13). A 95% detection limit was calculated by probit analysis using 12 replicates of serial dilutions according to the WHO international standard (6329/10, Paul Ehrlich Institute, Germany) to obtain volumes of 25,000, 2,500, 250, 200, 150, 100, 50, 25, and 2.5 HEV RNA international units (IU)/mL. The detection limit predicted for this PCR was 240 IU/mL (95% confidence interval: 173–513). Patient samples were tested in triplicate with negative controls included in each run, in addition to serial dilutions of the HEV reference standard. For HEV RNA real-time PCR sample amplification with undefined results, the Eurobio® commercial kit (Les Ulis, France) commercial kit was used. All assays were performed according to the manufacturer’s instructions. The staff involved in the HEV laboratory test was blinded to the patients’ clinical, biochemical, or histological data.

**Ethical considerations**
The study was performed in accordance with the principles of the Declaration of Helsinki. The protocol was approved by the institutional ethics board (number 138.009), and written informed consent was obtained from all participants.

**Statistical analysis**
Categorical variables are summarized as absolute and relative frequencies and continuous variables with median and interquartile ranges. Pearson chi-squared tests were performed to compare proportions, where appropriate. T-tests with Welch’s corrections were performed to compare the means of continuous variables. Further, logistic regression analysis was performed to assess the impact of HEV infection on the occurrence of diabetes mellitus. Woolf test of homogeneity of strat odds ratios (case versus control) and Cochran–Mantel–Haenszel test were performed to compare histological variables. Statistical analyses were conducted using the R statistical software (25).

### RESULTS

Anti-HEV IgG was detected in 22 (12.0%) patients and anti-HEV IgM in 3 (1.6%). Only one patient (1.8%) was seropositive for both anti-HEV IgG and IgM antibodies (Table 1). HEV RNA quantification by qRT-PCR showed weak evidence of amplification in nine (4.9%) patients, a result considered inconclusive. These nine samples were further tested by quantitative PCR amplification using the Eurobio® commercial kit, and all of them showed negative results for HEV RNA.

Study participants were divided into the mono-infected HCV group and HCV with HEV marker-positive group (HEV-HCV group). As shown in Table 2, no significant differences in baseline characteristics were detected between groups, except the higher prevalence of diabetes mellitus in the HCV-HCV group (21.0% versus 52%, p = 0.003) and differences in platelet count (p < 0.001).

A multiple logistic regression model suggested that the odds of positive HEV serology for patients with diabetes was 3.65 (95% CI 1.40–9.52) times the corresponding odds for patients without diabetes with the same severity of liver fibrosis, regardless of age. Furthermore, the odds of positive HEV markers for patients with grade F3/F4 fibrosis was multiplied by 3.91 (95% CI 1.38–11.06) for patients with diabetes, regardless of age (Table 3).

Data regarding liver disease severity as defined by the grade of liver fibrosis, clinical complications of cirrhosis, and Model For End-Stage Liver Disease (MELD) and Child–Pugh scores are summarized in Table 4. Liver fibrosis evaluation using FibroScan® was performed in 122 of 181 patients, whereas APRI and FIB-4 scores were calculated for 180 and 179 patients, respectively. No significant differences between groups regarding Child–Pugh or MELD scores, prevalence of esophageal varices, or frequency of hepatic encephalopathy and ascites were observed. However, a significantly higher

| Table 1 - Frequency of patients with chronic hepatitis C with different combinations of HEV test results. |
|-------------------------------------------------|---------------------------------|---------------------------------|---------------|
| Real-time | Anti-HEV IgM | Anti-HEV IgG | Frequency |
| Negative | Negative | Negative | 157 |
| Negative | Negative | Positive | 21 |
| Negative | Positive | Negative | 2 |
| Negative | Positive | Positive | 1 |
| Total | 181 |

HEV, hepatitis E virus; Ig, immunoglobulin.
prevalence of advanced liver fibrosis, as assessed by non-invasive methods, was detected in the HEV-HCV group. It is noteworthy that 63% and 67% of the patients in the HEV-positive group were found to have higher values of APRI (X\textsuperscript{1.45}) and FIB-4 (X\textsuperscript{3.25}) than 30% and 29% in the HCV mono-infected group, respectively (p=0.003 and p=0.001, respectively).

In the HEV-positive group, 18 patients (75%) had a higher fibrosis grade than 61 patients (39%) in the HCV mono-infected group (p=0.002), independent of the method used to classify liver fibrosis, confirming the more severe grade of liver fibrosis.

The case-control-based histological analysis (n=11 HEV-HCV and n=22 HCV patients) showed no significant differences between groups for the following parameters: portal inflammatory infiltrate, interface activity, parenchymal activity, steatosis, steatohepatitis, ballooning, Mallory hyaline, portal and lobular infiltrate (plasma cells, eosinophils, and neutrophils), biliary changes, and Kupffer cell siderosis.

### Table 2 - Demographic, clinical and laboratorial exams characteristics of patients with anti-HEV-positive and -negative antibodies.

| Variable                  | HCV group | HEV-HCV group |
|---------------------------|-----------|---------------|
| Age (years)               | n/total   | mean ± SD or %| n/total | mean ± SD or % | p-value |
| Male                      | 73/157    | 52.5 ± 12.9   | 9/24   | 57.0 ± 10.4    | 0.070   |
| Weight (kg)               | 150       | 71.8 ± 15.3   | 23     | 73.4 ± 23.3    | 0.757   |
| Height (cm)               | 148       | 164.5 ± 9.9   | 23     | 161.2 ± 12.7   | 0.243   |
| BMI (kg/m\textsuperscript{2}) | 148     | 28.5 ± 5.1    | 23     | 27.8 ± 6.8     | 0.343   |
| Arterial Hypertension     | 68/151    | 45%           | 13/23  | 57%            | 0.421   |
| Diabetes mellitus         | 32/151    | 21%           | 12/23  | 52%            | 0.003*  |
| Dyslipidemia              | 22/151    | 15%           | 3/23   | 13%            | 1       |
| Glucose                   | 148       | 102.9 ± 49.4  | 23     | 128.7 ± 78.7   | 0.140   |
| Insulin                   | 48        | 15.4 ± 10.6   | 6      | 26.4 ± 18.4    | 0.208   |
| HOMA                      | 46        | 4.2 ± 3.4     | 6      | 11.0 ± 10.1    | 1       |
| Albumin (g/dL)            | 154       | 4.2 ± 0.5     | 24     | 4.0 ± 0.6      | 0.996   |
| Alpha-fetoprotein (ng/mL) | 147       | 53.5 ± 323.0  | 23     | 14.2 ± 29.8    | 0.153   |
| ALT (U/L)                 | 157       | 65.6 ± 48.1   | 24     | 61.8 ± 52.1    | 0.739   |
| AST (U/L)                 | 157       | 60.5 ± 49.2   | 24     | 67.3 ± 48.5    | 0.527   |
| Total bilirubin (mg/dL)   | 157       | 0.8 ± 0.6     | 24     | 0.9 ± 0.4      | 0.171   |
| Creatinine (mg/dL)        | 155       | 1.3 ± 1.8     | 24     | 1.2 ± 2.0      | 0.864   |
| Platelets (10\textsuperscript{3}/mm\textsuperscript{3}) | 156     | 182.1 ± 75.6  | 24     | 116.5 ± 59.3   | <0.001* |
| Hemoglobin (g/dL)         | 156       | 14.0 ± 1.8    | 24     | 13.2 ± 2.5     | 0.111   |
| INR                       | 153       | 1.1 ± 0.3     | 24     | 1.1 ± 0.2      | 0.723   |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HCV, hepatitis C virus; HEV, hepatitis E virus; HOMA, homeostasis model assessment; INR, international normalized ratio; SD, standard deviation; *p<0.05.

### Table 3 - Results of multiple logistic regression model with HEV positivity as response variable and diabetes mellitus, age, and grade of liver fibrosis (F0/F1/F2 or F3/F4) as explanatory variables.

| Coefficient | Estimate | Standard error | p-value |
|-------------|----------|----------------|---------|
| Intercept   | -3.11    | 1.16           | 0.01*   |
| Diabetes mellitus | 1.30 | 0.49 | 0.01*   |
| Fibrosis F3/F4 | 1.36 | 0.53 | 0.01*   |
| Age         | -0.0002  | 0.02           | 0.02*   |

HEV, hepatitis E virus. *p<0.05.

### Table 4 - Comparison of HEV-HCV patients and HCV mono-infected patients regarding liver disease severity.

| Variable                  | HCV group | HEV-HCV group |
|---------------------------|-----------|---------------|
| Grade of fibrosis (F3/F4) | n/total   | mean ± SD or %| n/total | mean ± SD or % | p-value |
| FibroScan >9.5 kPa        | 39/110    | 36%           | 8/12    | 67%           | 0.072   |
| APRI >1.45                | 46/156    | 30%           | 15/24   | 63%           | 0.003*  |
| FIB-4 score >3.25         | 44/154    | 29%           | 16/24   | 67%           | 0.001*  |
| Asites                    | 12/44     | 27%           | 6/15    | 40%           | 0.549   |
| Encephalopathy            | 5/44      | 11%           | 3/15    | 20%           | 0.684   |
| Esophageal varices        | 33/44     | 75%           | 11/15   | 73%           | 1       |
| Child-Pugh A              | 31/44     | 71%           | 9/15    | 60%           | 0.668   |
| MELD                      | 43        | 10.3 ± 3.5    | 15      | 9.2 ± 1.6     | 0.109   |

APRI, AST to platelet ratio index; FIB-4, Fibrosis-4; HCV, hepatitis C virus; HEV, hepatitis E virus; SD, standard deviation; MELD, Model For End-Stage Liver Disease. *p<0.05.
HEV infection in chronic HCV patients
Zitelli PMY et al.

DISCUSSION

In this study of naive HCV-infected patients, we found an association between HEV infection markers (anti-HEV IgM and IgG) and comorbidities and severity of a liver disease. The 12% of patients in this study showed HEV infection, which was significantly associated with a higher frequency of diabetes mellitus and advanced liver fibrosis. However, a comprehensive liver histological analysis did not suggest any particular findings of HEV infection in these patients.

In Brazil, the prevalence of HEV infection in blood donors and the general population is 3%-7% (4). In the present study, the seroprevalence of HEV was 12% among patients with chronic HCV infection and without previous antiviral treatment. This prevalence is higher than that reported in previous studies of the general population in Brazil. Recently, Bricks et al. reported a similar HEV seroprevalence of 10.2% in patients with chronic HCV infection. However, they mention that 37.4% of patients were treated for HCV infection, which may underestimate this prevalence since pegylated interferon, ribavirin, and other antivirals can eliminate HEV (13).

HEV RNA amplification with real-time PCR showed inconclusive results for nine patients, not allowing us to ascertain the positivity of infection. Therefore, we re-evaluated the corresponding blood samples using the HEV Eurobio® commercial kit and obtained negative results. Differences in sensitivity and specificity between various commercial serological kits and HEV RNA PCR assays have been reported (14). The lack of a suitable gold standard method for diagnosing HEV infection hampers the distinction between true-positive and false-positive cases (15-17). Furthermore, HEV antibodies lack neutralizing activity, and re-infection may occur in both immunocompromised and immunocompetent hosts. Norder et al. compared five serological assays for HEV detection based on the following commercial kits: Mikrogen, DSL, Euroimmun, Axiom, and DiaPro. They noted that despite the high sensitivity for anti-HEV detection, serum samples from immunocompetent patients with HEV RNA were detected without serological markers for HEV (18).

HCV infection is associated with several conditions or extrahepatic manifestations. Among these, diabetes has been studied in depth (19). In addition, HCV infection can induce changes in insulin signaling, causing a blockage in the release and action of insulin and thereby preventing its role in regulating glucose metabolism in the body, that is, it directly promotes insulin resistance (20). In our study, an association was found between positive HEV serology and diabetes mellitus, controlled for age and severity of liver fibrosis, with an odds of 3.65 (95% CI 1.40–9.52) times the corresponding odds in those without diabetes but with the same severity of liver fibrosis, regardless of age. Furthermore, the odds of positive HEV markers for patients with grade F3/F4 fibrosis was multiplied by 3.91 (95% CI 1.38–11.06) for patients with diabetes, regardless of age.

Another Brazilian study recently reported interesting results related to glycemic status and HEV infection. The authors showed an association between insulin resistance and the presence of HEV antibodies, adjusted for age, body mass index, and cirrhosis (odds ratio=4.39; p=0.045) (21). This indicates that HCV infection may increase the risk of developing diabetes, but the HEV-positive markers in HCV patients appear to increase this risk further.

In this study, METAIVIR grade 3 and 4 hepatic fibrosis and liver stiffness measurements and higher values of a non-invasive index to predict significant fibrosis using APRI and FIB-4 were more frequent in HEV-positive patients than in HEV-negative patients (p=0.002). Other studies have observed similar results, showing that patients with underlying liver disease have a worse prognosis when infected with HEV. For example, a study conducted in the UK and France tested 343 patients with chronic liver disease and showed that 3.2% (n=11) of the patients had acute hepatitis E infection with anti-IgM or HEV PCR positivity, three of whom died. In addition, the authors observed seropositive anti-IgG antibodies in 64 of 321 (19.9%) patients (22).

Wallace et al. analyzed 511 HEV-infected patients in a multicenter retrospective study in Scotland. Among them, 11% (n=58) had pre-existing cirrhosis and 21% (n=110) had diabetes. Seventeen (3.3%) HEV-related deaths were recorded, and the following factors were associated with mortality: hematological malignancy (p=0.005), cirrhosis (p=0.006), higher serum bilirubin level (p=0.011), and chronic HEV infection (p<0.001). Further, 35 (6.7%) patients developed acute hepatitis, acute-on-chronic liver failure, or acute deterioration of cirrhosis, with two patients requiring liver transplantation. The authors concluded that cirrhosis and diabetes were significantly associated with symptomatic HEV infection. The presence of underlying liver disease worsens prognosis (23).

A study conducted in China showed more complications and hepatic failure when patients with chronic HBV and HEV superinfection were than patients with chronic HBV and HAV superinfection (94.9% versus 61.5%, p<0.001, and 39.7 versus 11.5%, p=0.002, respectively). Furthermore, they demonstrated higher mortality in the chronic HBV plus HEV group (33.8 versus 1.9%, p<0.001) (24).

A limitation of the present study is that we could not determine the time of HEV or HCV infection. These infections are usually asymptomatic, and patients with HEV infection are usually viremic for 2 weeks. Furthermore, the discrepancy of differences in sensitivity and specificity between the various commercial serological kits and HEV RNA PCR assays makes it difficult to diagnose HEV infection.

In summary, the seroprevalence of HEV was high in this study, and HEV infection may influence the severity of liver disease and represent an additional risk of developing diabetes mellitus and liver decompensation in patients with HCV infection.

AUTHOR CONTRIBUTIONS

Pessoa MG conceived and designed the study, cared for the patients, contributed to the data analysis and interpretation, and wrote and reviewed the manuscript. Zitelli PMY collected and assembled the data, processed the biological samples, contributed to the analysis and interpretation, and wrote the manuscript. Gomes-Gouvêa M and Pinho JR processed the HEV laboratory test and analyzed the results. Singer JM contributed to the statistical analysis and interpretation of the results. Mazo DF, Oliveira CPMS, Farías AQ, and Carrilho EF cared for the patients and critically reviewed the manuscript. Tanigawa RY and Alves VAF histologically assessed liver biopsy slides. All authors critically reviewed the manuscript, approved the final version to be published, and agreed to be accountable for all aspects of the work.
REFERENCES

1. Dreijer JJ, Seelen A, Corman VM, Fumie Tateno A, Cottontail V, Melim Zerbinati R, et al. Bats worldwide carry hepatitis E virus-related viruses that form a putative novel genus within the family Hepeviridae. J Virol. 2012;86(17):9343-47. https://doi.org/10.1128/JVI.00800-12

2. Aggarwal R. Diagnosis of hepatitis E. Nat Rev Gastroenterol Hepatol. 2013;10(1):24-33.

3. Lhomme S, Marion O, Abravanel F, Chapuy-Regaud S, Karnar N, Ienopet J. Hepatitis E Pathogenesis. Viruses. 2016;8(6):212. https://doi.org/10.3390/v8060212

4. Aggarwal R, Goel A. Advances in hepatitis E: virology, pathogenesis and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10(10):1053-63. https://doi.org/10.1080/17474124.2016.1185362

5. Kamar N, Ienopet J, Paviño N, Aggarwal R, Labrique A, Wedemeyer H, et al. Hepatitis E virus infection. Nat Rev Dis Primers. 2017;3:17086.

6. Yazbek S, Kreidieh K, Ramia S. Hepatitis E virus in the countries of the Middle East and North Africa region: an awareness of an infectious threat to blood safety. Infect. 2016;44(1):11-22. https://doi.org/10.1007/s15010-015-0807-5

7. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, et al. Seroprevalence of hepatitis E virus in chronic hepatitis C in Brazil. Rev Soc Bras Med Trop. 2015;48(4):468-70. https://doi.org/10.1590/0037-8682-0036-2015

8. Carrilho FJ, Mendes Clemente C, Silva LC. Epidemiology of hepatitis E virus infection in Brazil: results of laboratory-based surveillance from 1998 to 2013. Rev Soc Bras Med Trop. 2015;48(4):468-70. https://doi.org/10.1590/0037-8682-0036-2015

9. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, et al. Seroprevalence of hepatitis E virus in chronic hepatitis C in Brazil. Mem Inst Oswaldo Cruz. 2001;96(1):25-9. https://doi.org/10.1590/S0074-02762001000100004

10. Tengan FM, Figueiredo GM, Nunes AKS, Manchiero C, Dantas BP, Magri MC, et al. Seroprevalence of hepatitis E in adults in Brazil: a systematic review and meta-analysis. Infect Dis Poverty. 2019;8(1):3. https://doi.org/10.1186/s40249-018-0514-4

11. Bricks G, Senise JF, Pott Junior H, Grandi G, Passarini A, Caldeira DB, et al. Seroprevalence of hepatitis E virus in chronic hepatitis C in Brazil. Braz J Infect Dis. 2018;22(2):85-91. https://doi.org/10.1016/j.bjid.2018.02.003

12. Tengan FM, Figueiredo GM, Nunes AKS, Manchiero C, Dantas BP, Magri MC, et al. Two Generations of “Gold Standards”: The Impact of a Decade in Hepatitis E Virus Testing Innovation on Population Seroprevalence. Am J Trop Med Hyg. 2015;93(4):714-7. https://doi.org/10.4269/ajtmh.15-0159

13. Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol. 2017;23(9):1697-711. https://doi.org/10.3748/wjg.v23.i9.1697

14. Bricks G, Senise JF, Pott Jr H, Grandi G, Carneir “da J, Monteiro A, et al. Previous hepatitis E virus infection, cirrhosis and insulin resistance in patients with chronic hepatitis C. Braz J Infect Dis. 2019;23(1):45-52. https://doi.org/10.1016/j.bjid.2019.02.002

15. Slavos-Perrin H, Madden R, Stanley A, Crosson C, Hunter JG, Vine L, et al. Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study. Aliment Pharmacol Ther. 2015;42(5):574-81. https://doi.org/10.1111/apt.13309

16. Wallace SJ, Swann R, Donnelly M, Kemp L, Guacci J, Murray A, et al. Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective study. Aliment Pharmacol Ther. 2020;51(10):974-86. https://doi.org/10.1111/apt.15704

17. Zhang X, Ke W, Xie J, Zhao Z, Xie D, Gao Z. Comparison of effects of hepatitis E or A viral superinfection in patients with chronic hepatitis B. Expert Rev Gastroenterol Hepatol. 2016;10(9):1053-63. https://doi.org/10.1080/17474124.2016.1185362

18. Sagnelli E, Coppola N, Pisaturo M, Masiello A, Tonziello G, Sagnelli C, et al. Seroprevalence of hepatitis E virus in chronic hepatitis C in Brazil. Rev Soc Bras Med Trop. 2015;48(4):468-70. https://doi.org/10.1590/0037-8682-0036-2015

19. Bricks G, Senise JF, Pott Jr H, Grandi G, Passarini A, Caldeira DB, et al. Seroprevalence of hepatitis E virus in chronic hepatitis C in Brazil. Braz J Infect Dis. 2018;22(2):85-91. https://doi.org/10.1016/j.bjid.2018.02.003

20. Kuros S, Higuchi R. Avoiding false positives with PCR. Nature. 1989;339(6221):237-8. https://doi.org/10.1038/339237a0

21. Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, et al. Hepatitis E virus serology and PCR: does the methodology matter? Arch Virol. 2017;162(9):2625-32. https://doi.org/10.1007/s00705-017-3395-0

22. Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol. 2012;50(8):2708-13. https://doi.org/10.1128/JCM.01119-12

23. Wallace SJ, Swann R, Donnelly M, Kemp L, Guacci J, Murray A, et al. Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicenter retrospective study. Aliment Pharmacol Ther. 2020;51(10):974-86. https://doi.org/10.1111/apt.15704

24. Zhang X, Ke W, Xie J, Zhao Z, Xie D, Gao Z. Comparison of effects of hepatitis E or A viral superinfection in patients with chronic hepatitis B. Hepatol Int. 2016;10(4):615-20.

25. R Core Team. R: A language and environment for statistical computing. Vienna, Austria. Available from: https://www.r-project.org/